Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Today, except for Non-small-cell lung carcinoma (NSCLC) harboring targetable oncogenes, nearly all patients with Non-small-cell lung carcinoma (NSCLC) receive PD-1 or PD-L1 therapy in first-line settings.
Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]1) targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated in NCT02888743 the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy.
Schoenfeld et al. 2022 The …